Mozobil (plerixafor, AMD-3100)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Mozobil |
| Generic Name: | plerixafor |
| Code Name: | AMD-3100 |
| Company: | Genzyme |
| FDA Clinical Phase: | Approved for use with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into the peripheral blood for collection and subsequent autologous transplantation in multiple myeloma patients |
Description:
Mozobil is a member of a new class of medications called “chemokine inhibitors”. The drug triggers the movement of stem cells out of the bone marrow into the blood stream. Larger stem cell doses for transplantation are correlated to faster recovery times after high dose chemotherapy followed with stem cell transplantation.
Clinical Trials:
Currently, there are several open clinical studies involving Mozobil.
Source: ClinicalTrials.gov, Multiple Myeloma AND Mozobil, http://www.clinicaltrial.gov/ct2/results?term=multiple+myeloma+AND+Mozobil (as of September 4, 2008)
Related Articles:
- Mozobil With Neupogen Increases Stem Cell Harvest Efficiency
- Mozobil May Help Myeloma Patients Collect Enough Stem Cells For A Second Transplant
- Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells
- FDA Approves Mozobil For Myeloma Patients Preparing For Stem Cell Transplants
- Expert Panel Recommends European Approval Of Mozobil
Leave a comment